[TREATMENT OF HOMOZYGOTES OF FAMILIAL HYPERCHOLESTEROLEMIA: RECOMMENDATIONS OF THE ISRAELI SOCIETY OF ATHEROSCLEROSIS].

Cohen, Hofit; Durst, Ronen; Elis, Avishay; Gavish, Dov; Schurr, Daniel

Cohen, Hofit; Durst, Ronen; Elis, Avishay; Gavish, Dov; Schurr, Daniel.

Afiliação

Cohen H; The Bert W. Strassburger Lipid Center, the Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Durst R; Center for Prevention and Treatment of Atherosclerosis, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Elis A; Department of Internal Medicine, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
Gavish D; Cardiovascular Research Center, Edith Wolfson Medical Center, Holon, Israel.
Schurr D; Cardio-Metabolic Clinic, Shaare Zedek Medical Center, Jerusalem, Israel.

Harefuah ; 160(3): 170-174, 2021 Mar.

Article em He | MEDLINE | ID: mdl-33749180

Assuntos

Anticolesterolemiantes; Aterosclerose; Hiperlipoproteinemia Tipo II; Aterosclerose/genética; Aterosclerose/terapia; LDL-Colesterol; Homozigoto; Humanos; Hiperlipoproteinemia Tipo II/diagnóstico; Hiperlipoproteinemia Tipo II/genética; Hiperlipoproteinemia Tipo II/terapia; Pró-Proteína Convertase 9

Buscar no Google

Imprimir

XML

PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aterosclerose / Hiperlipoproteinemia Tipo II / Anticolesterolemiantes Tipo de estudo: Diagnostic_studies / Guideline / Risk_factors_studies Limite: Humans Idioma: He Revista: Harefuah Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Israel

Buscar no Google

Imprimir

XML

PubMed Links